Technical / White Paper
Next-Generation Orphan Drug Delivery Ebook
According to the National Organization for Rare Disorders (NORD), a disease is rare if it affects fewer than 200,000 Americans. Big Pharma used to ignore this segment of the market, but now developing orphan drugs to treat these rare diseases is an industry priority. Driving efficient timelines is a key to bringing products to market on an accelerated track. If you don’t have formulation, analytical, clinical, and manufacturing resources and infrastructure in-house, maintaining a development programs that takes full advantage of an expedited designation from the FDA can be challenging.